Frequently Asked Questions
The market is segmented based on Segmentation, By Test Type (Dried Blood Spot Test, Hearing Screen Test, Critical Congenital Heart Diseases (CCHD) Test), Product Type (Instruments, Reagents, Assay Kits), Technology (Tandem Mass Spectrometry, Hearing Screen Technology, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, Electrophoresis, DNA-Based Assays), Disease Type (Critical Congenital Heart Diseases, Newborn Hearing Loss, Sickle Cell Disease, Phenylketonuria (PKU), Cystic Fibrosis (CF), Maple Syrup Urine Disease, Others), End User (Hospital, Paediatric Clinics, Clinics) – Industry Trends and Forecast to 2031
.
The Global Newborn Screening Market size was valued at USD 1.07 USD Billion in 2023.
The Global Newborn Screening Market is projected to grow at a CAGR of 8.8% during the forecast period of 2024 to 2031.
The major players operating in the market include PerkinElmer , Demant A/S, Natus Medical orporated, BioRad Laboratories, Luminex Corporation, F. Hoffmann, La Roche , Thermo Fisher Scientific , Bruker, Danaher, Medtronic, Chromsystems Instruments & Chemicals GmbH, Trivitron Healthcare, Baebies , RECIPE Chemicals + Instruments GmbH..
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.
